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Introduction
 To measure the health benefits of innovative 
pharmaceuticals, health technology assessment (HTA) 
methods are useful when making insurance coverage 
decisions (M. F. Drummond et al., 2008). For the purpose of 
containing pharmaceutical expenditures, a positive listing 
system of reimbursable drugs was introduced in December 
2006 under the Drug Expenditure Rationalization Plan in 
Korea. Under this policy, pharmaceutical manufacturers 
submit clinical and economic evidence of a new drug to 
the Health Insurance Review and Assessment Service 
(HIRA) in their reimbursement applications. After HIRA 
approves the listing the new drug moves to the next phase 
of negotiating its final price with the National Health 
Insurance Corporation. Most pharmaceutical companies 
have expressed concerns over this policy, arguing that it 
may exert a negative effect on the development of new 
innovative drugs by favouring cheaper drugs over novel 
drugs, that, although expensive, provide reasonable 
value for the cost (Kwon, 2009). The presence of a 
limited number of experts to carry out, interpret, and 
evaluate such economic outcomes has also aggravated the 
worries of pharmaceutical companies in Korea. However, 
following the economic climate prevalent in single-payer 
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health systems, most global and local pharmaceutical 
companies have come to agree on the need to provide 
cost-effectiveness outcomes to the payer (Yang, 2009). 
 In an effort to rapidly implement HTA, both 
pharmaceutical companies and HIRA in Korea have 
been emulating the organizational and methodological 
experience of established HTA systems such as those 
in Australia, Canada, and the United Kingdom (UK) 
(Kamae, 2010; Oortwijn et al., 2010). Based on the 
critical assessment conducted by HIRA, the Drug 
Reimbursement Evaluation Committee (DREC), 
consisting of representatives from medical associations 
and consumer interest groups, determines whether to 
fund the drug. According to HIRA guidance, technical 
factors DREC should consider are: (i) the availability of 
therapeutic alternatives and indispensability in the clinical 
setting; (ii) clinical effectiveness; (iii) cost-effectiveness; 
(iv) budget impact; and (v) the listing situation of the 
drug in other countries (Health Insurance Review and 
Assessment Service (HIRA), 2007). 
 As in other countries, no arbitrary fixed willingness to 
pay threshold for accepting incremental cost-effectiveness 
ratio (ICER) values has been officially designated in 
Korea. However, the per capita gross domestic product 
is usually referred to in determining the acceptability 
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of ICER throughout DREC’s decision making-process 
(Yang, 2009). Although interpreting the ICER measure 
seems relatively simple, explicit, and even transparent, it 
creates a conceptual problem in terms of vertical equity 
over equality (Schlander and Beck, 2009; Hauck and 
Tsuchiya, 2011). For example, the initial health states 
of individuals are not directly considered (Schlander 
and Beck, 2009). Furthermore, valuation related to loss 
of quality of life may also vary across different age 
and disease contexts (Weinstein, 1988). Accordingly, 
ICER evidence-based reimbursement policies have been 
criticized for limiting access to new novel treatments, 
which are typically modestly effective but extremely 
expensive, especially for cancer patients (Low, 2007; 
Rocchi et al., 2008; Schnipper et al., 2010). In fact, 
while oncology drugs seem to have a higher threshold 
of acceptability compared with non-oncology drugs by 
decision-makers, those with higher ICER values have 
been associated with constrained access and slower time 
to coverage in HTA systems (Rocchi et al., 2008; Chim 
et al., 2010). 
 In addition to evidentiary and scientific values, 
responsible decision-makers should make judgments 
using non-evidentiary and ethical values in a context-
sensitive approach to determine what is good for society 
(Rawlins and Culyer, 2004; Burls et al., 2011). Moreover, 
people will accept drug coverage decisions only if they 
are assured that the rationales for the limits to new drug 
therapies are relevant to the society’s needs under a 
fair and transparent decision-making process (Daniels 
et al., 2003; Drummond et al., 2009). Although ethical 
considerations are the inherent notion of HTAs, it has been 
argued that the present HTA evaluations do not sufficiently 
reflect the ethical implications in the HTA process, even 
in the HTA-leading countries (Hofmann, 2008; DeJean et 
al., 2009). 
 With this background in mind, we aimed to discover 
to what extent ethical values were prudently considered or 
addressed in the reimbursement decision process. For this 
purpose, we systematically analyzed public documents 
for DREC’s reimbursement decisions regarding oncology 
drugs in Korea. 
 
Materials and Methods
 Public summary documents (PSDs) regarding DREC’s 
reimbursement decisions began to be published online 
at the HIRA website (http://www.hira.or.kr/) in 2011, 
almost 3 years after the introduction of the positive 
listing system. The publication was operated from the first 
dossier completed with a reimbursement decision in the 
order. For this study, we collected PSDs for cancer drugs 
published online until April 2011, when the PSDs were 
downloaded from the HIRA website by the authors. For 
external comparison of empirical evidence, we searched 
the corresponding PSDs of the Pharmaceutical Benefits 
Advisory Committee of Australia (PBAC) (http://www.
health.gov.au/internet/main/publishing.nsf/Content/
public-summary-documents). If related PSDs were not 
identified from the PBAC webpage, guidance papers 
released by the National Institute for Health and Clinical 
Excellence (NICE) of the UK were obtained (http://www.
nice.org.uk/Guidance/TA).
 The authors and an analyst scrutinized these PSDs to 
examine if the evidentiary factors were used with clear 
relevance and ethical considerations in the decision-
making process. The empirical factors evaluated, such 
as comparators, economic and clinical claims, and other 
decision contexts, were summarized into tables to allow 
for a brief comparison between decision-making bodies. 
Pertinent substances and key points in each decision were 
also identified and documented by each author. In the same 
way, the PSDs of PBAC and NICE were summarized by 
the authors. These summaries were subsequently made 
into a table for a comparison of PSDs between decision-
making bodies. 
 We invited one or two oncologists per relevant 
subspecialty (such as leukaemia, breast cancer, and 
colorectal cancer), for an in-depth interview. This was 
specifically undertaken to assess the stakeholders’ 
comments or suggestions pertaining to the new oncology 
drugs submitted to, and reviewed by, HIRA. All eight 
oncology experts were selected by the recommendation 
of the cancer centre’s chairman at a university hospital, 
considering the expert’s previous experience with clinical 
research for the purpose of producing input data for the 
HTA reports. To help the interviewee understand the 
decisions, each oncologist received his/her subspecialty-
relevant summarized table via e-mail one week before 
the interview. A three- to four-hour interview session was 
scheduled separately for each of the eight oncologists. 
 At the beginning of each interview, the authors briefly 
explained to the interviewee the reimbursement decision 
process and the values of evidentiary factors on the PSDs. 
The questions or comments the interviewee brought up 
about the summaries were answered and discussed. Then, 
the authors asked questions which were prepared by the 
authors in advance after having summarized and compared 
the PSDs. The number of questions varied from four to 13 
depending on the issues about the drug and the evaluation 
contents in the PSDs. For example, the interviewees were 
asked about their opinions and judgments regarding the 
needs and utilization changes within the real health care 
system on the assumption that cetuximab was reimbursed 
under a risk sharing model, which was the case in PBAC 
decisions. 
 In addition to efforts identifying social and ethical 
considerations (such as equity or historical precedent), 
the fairness of the decision-making process setting was 
evaluated by inference from the PSDs. Finally, the authors 
extracted qualitative key themes among ethical dimensions 
which appeared to have not received the consideration 
they may have deserved from the decision-makers. 
Results 
Reimbursement decisions
 Drug reimbursement decisions made from January 
2007 to June 2009 were available when the authors 
drew the PSDs from the HIRA website in 2001. In this 
period, approximately 100 new drugs were reviewed for 
reimbursement decisions, including 12 oncology drugs 
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(Table 1). Among the 12 oncology drug applications, 
eight were submitted by global pharmaceutical companies, 
while the other four were submitted by the non-profit 
Korea Orphan Drug Centre or wholesale trade companies. 
Data of cost-effectiveness models were included in four 
dossiers, all of which were developed and submitted by 
global manufacturing pharmaceutical companies (Table 
1).
 Starting with dasatinib, five cancer drugs were 
approved for reimbursement during the period. With 
the exception of dasatinib, which was listed on the 
Korean national formulary relatively earlier than in other 
countries, the other four reimbursement-approved drugs 
had been listed beforehand in other reference countries 
during the period of HIRA’s review process. According 
to the PSDs of HIRA, PBAC and NICE had approved 
coverage for two and five oncology drugs, respectively. 
Indeed, the statement that “Australia and the UK had 
not listed cetuximab” in the PSD on the submission for 
cetuximab suggested that among reference countries, the 
reimbursement decisions of Australia and the UK were 
given more weight by DREC. 
 We identified five public documents of PBAC and 
two of NICE on corresponding public documents. Tables 
2 and 3 summarize the empirical factors considered by 
HIRA in comparison with PBAC and NICE. Differing 
recommendations were made by DREC and PBAC 
for cetuximab and topotecan, for which the decisions 
of DREC were made earlier than PBAC (Table 2). 
Fulvestrant and trabectedin were rejected by DREC while 
they had been under review by NICE (Table 3). 
Relevance of empirical factors
 Rationale and revision for the ICERs evaluated: All 
applications reviewed by PBAC presented economic 
modelling data consisting of cost-effectiveness or cost-
utility model analysis data, except nilotinib, which was 
submitted with a cost-minimization approach. The ICER 
value of nilotinib was not accepted, and a conditional 
approval upon agreeing to a weighted average cost of 
comparators was recommended by DREC, which is 
essentially the same approach as a cost-minimization 
strategy (Table 2). 
 The ICER values usually appeared irrelevant to 
DREC’s confidence as expressed by sentences in the 
PSDs. Because the ICER value is certainly relevant, 
a strategy of setting a comparable price rather than 
submitting pharmacoeconomic modelling data might work 
more usefully in achieving market positioning with less 
time and minimal resources consumed in their preparation. 
Since the comparator had long been criticized for its 
expensive price in Korea, a reimbursement application for 
dasatinib was prepared using this strategy. Intuitively, the 
new drug’s lower price would lighten the decision-makers’ 
Table 1. Oncology Drugs Assessed by the Drug Reimbursement Evaluation Committee (DREC) between January 
2007 and June 2009
Oncology drug Oncology drug Indication Sponsor DREC 
meeting date
Decision 
result
CE 
evidence 
submission
Reference 
countries for listing
Sprycel Dasatinib 
70, 50, 20.mg
CML BMS 
Korea
Jul 20, 2007 Approval n/s n/m
Erwinase L-asparaginase 
10,000 IU
ALL BL&H Oct 19, 2007 Rejection n/s n/m
Oncaspar Pegaspargase 
3,750 IU/5 mL
ALL KODC Oct 19, 2007 Rejection n/s n/m
Dacogen Decitabine 
50 mg
Myelodysplastic 
syndromes
Janssen
Korea
Dec 21, 2007
Feb 22, 2008
Approval n/s US
Erbitux Cetuximab 
100, 50 mg
Colorectal cancer Merck Feb 22, 2008
May 21, 2008
Rejection Submitted Not listed: 
Australia, UK
Vorina inj. 2.5% Sodium folinate 
100, 300 mg
Leukemia as an 
adjuvant
Myungji
Pharm
Jan 25, 2008
Sep 26, 2008
Rejection n/s Germany
Faslodex Fulvestrant 
250 mg/5 mL
Metastatic 
breast 
cancer
Astra 
Zeneca
Korea
Apr 25, 2008
Sep 26, 2008
Rejection Submitted US, UK, Italy, France, 
Germany, Switzer-
landa
Nipent inj. 
10mg
Pentostatin 
10 mg
Hairy cell 
leukemia
DB Pharm
Korea
Mar 19, 2009 Rejection n/s US, UK, Italy
Hycamtin Topotecan 
HCl 0.27, 1.09 mg
SCLC GSK 
Korea
Jun 18, 2009 Approval n/s US, UK, France, 
Germany
Tasigna Nilotinib 
200 mg
CML Novartis
Korea
Oct 28, 2008
Aug 20, 2009
Approval Submitted US, Australia, 
Switzerland
Tykerb Lapatinib ditosylate 
250 mg
HER2-positive 
breast cancer
GSK
Korea
Jan 15, 2008
May 21, 2008
Nov 19, 2009
Approval Submitted US, France, Germany, 
Switzerland, UK, 
Australiab
Yondelis Trabectedin
0.25, 1.0 mg
Soft tissue 
sarcoma
Janssen
Korea
Jan 21, 2010
Mar 25, 2010
Rejection n/s UK, Germany, Italy
*CE, cost-effectiveness; n/s, not submitted; n/m, not mentioned; KODC, Korea Orphan Drug Center; CML, chronic myeloid leukemia; ALL, acute lymphoblastic 
leukemia; HER2, human epidermal growth factor receptor 2; SCLC, small cell lung cancer. aIn all reference countries, the drug was approved and listed as a second-line 
treatment. bFor Australia, pre-approval was required before using lapatinib
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burden considering the sum of insurance expenditures and 
budget impact outcomes (although the explicit values were 
not stated on the PSDs), leading to positive final decisions 
as in the case of dasatinib.
 Indeed, the inherent uncertainty in the economic 
models of DREC was often expressed in the PSDs. For 
example, in the PSDs with non-coverage decisions (such 
as cetuximab), lack of confidence in assumption or input 
data of economic modelling was stated as a causative 
factor, rather than the judgment being based on an explicit 
value like the ICER (Table 2). The fact that PBAC 
deliberated on cetuximab over seven meetings revealed 
that the complexity in economic modelling required 
time and back and forth endeavor to resolve specific 
technicalities in the HTA. However, the application of 
cetuximab was discussed only twice by DREC, after which 
it was rejected with no further deliberation allowed in the 
process of evaluating any empirical evidence. 
 Relevance of comparator selection: While best 
supportive care was admitted as a comparator of 
cetuximab, topotecan oral, and trabectidin by PBAC and 
NICE, none of new drugs were approved in DREC’s 
appraisal if they were compared with best supportive care 
(Tables 2 and 3). Indeed, except dasatinib, no oncology 
drug was acknowledged as a medical necessity by DREC, 
and dasatinib was also approved by PBAC under the Rule 
of Rescue guideline. 
 The absence of direct comparison in clinical trials has 
often propelled the conclusion of insufficient and unclear 
clinical efficacy by DREC. However, there are often 
limited treatment options available for terminal cancers. 
For example, there had been no standard second- or 
third-line treatment indications when early clinical trials 
of cetuximab were designed (Table 2). Furthermore, 
because some cancers occur very rarely (such as hairy cell 
leukemia), it would be difficult to ever construct a trial on a 
large enough scale to substantiate a clinical improvement. 
 Some comparators determined by DREC were disputed 
by the interviewee oncologists. For example, imatinib 800 
mg for the treatment of imatinib-tolerant patients and 
salvage therapy (S-1) of cetuximab as the comparator 
were considered unreasonable (Table 2). The assumption 
of trastuzumab continuation is also discordant with the 
actual care setting in Korea (Table 2). Furthermore, while 
asserting that trastuzumab cannot be the comparator for 
lapatinib, a contradictory statement was made in the PSD 
by DREC that the cost of lapatinib therapy was lower than 
the cost of trastuzumab. 
 Sometimes a technical solicitation of a “comparable” 
drug in economic modelling resulted in the selection of a 
comparator with less relevance. For example, PBAC did 
not consider bevacizumab as an appropriate comparator 
for cetuximab on the grounds that cetuximab therapy 
is more efficacious against K-RAS wild-type patients. 
However, the K-RAS type was unknown at the time 
when treatment commenced; thus, in reality, bevacizumab 
maintains its first-line treatment position and cetuximab 
is used for the treatment of bevacizumab failure (Table 
2). The clinical efficacy of oncology drugs typically 
varies across patients, indicating there may be a marker 
for choosing a patient group in which the drug will show 
the best efficacy. While such a marker for bevacizumab is 
unfortunately unknown, cetuximab has one that appears to 
work. Currently, the choice of the interviewee oncologists 
between cetuximab and bevacizumab depends on K-RAS 
type, in addition to the patient’s status in terms of gender 
and cardiovascular problems 
Considering ethical aspects 
 Exceptional conditions for reimbursement: The ICER 
of trabectedin over best supportive care (£34,500/quality-
adjusted life year) was approved with end-of-life criteria 
by NICE. However, it was rejected in the DREC decision 
by reason of non-submission of ICER figures (Table 3). 
Most of the oncologists interviewed thought that new drugs 
for rare cancers should be waived of economic evaluation 
for reimbursement decisions. Although these novel drugs 
are expensive, the budget impact of listing them will not 
be catastrophic from the insurer’s perspective because the 
patient pool is exceptionally small. Nonetheless, in the 
DREC reports, there was no case among oncology drug 
applications which were exempt from economic analyses 
and which involved ethical considerations.
 Some recently developed second- and third-line 
cancer drugs are for patients who have no other option 
due to failure of, intolerance to, or contraindication with 
the existing therapy. Indeed, even though the majority 
of patients may be treated with a first-line therapy, the 
second- and third-line treatment options need to be 
established in society for the treatment security of rare 
cancer patients. However, these drugs were likely to be 
rejected for coverage by reason of technical difficulties 
(such as lack of a clinical trial) or no submission of an 
ICER value with a particular comparator that was pre-
determined by DREC. 
 Accountability about reviewers: DREC is the only 
committee to review all reimbursement applications 
submitted to HIRA. However, as there was no clear 
HIRA guideline for examination for ethical issues in the 
technology assessment, there was no ethics specialist 
among the committee members. Furthermore, neither 
oncologists nor cancer patient representatives were 
included in DREC reviewing these new oncology 
drugs. Without seeking expert advice and stakeholder’s 
involvement, it would be hard to sufficiently reflect 
and convey the needs and values of the public in the 
technology assessment for new oncology drugs for 
reimbursement decisions. Indeed, HIRA seldom reported 
information about who had participated in meetings and 
potential committee member conflicts of interest on the 
PSDs.
 Equity in the choice of reimbursable cancer drugs: 
Dasatinib was acknowledged for its clinical indispensability 
by DREC, but nilotinib was not. Decitabine was approved 
while its alternative, azacitidine, was available in the 
listing (Table 1). In contrast, pentostatin was rejected 
on the concern that it might increase financial burden by 
replacing cladribine, which was not even being reimbursed 
at that time (Table 1). However, there was no obvious 
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Table 2. Empirical Factors in DREC Decisions on Reimbursement Applications for Cancer Drugs Compared 
with PBAC Decisions
Evaluation 
point
DREC Decision PBAC Decision
Dasatinib
Recommendation Approval (Jul 20, 2007) for both CML and ALL Approval for CML (Mar 2007); approval for ALL (Jul2007)
No. of Meetings One One for CML, two for ALL
Medical necessity Required
Comparators Imatinib 800 mg Imatinib resistant: 800 mg/day. Imatinib intolerant: 300-400 mg/day
Clinical evidence For imatinib-tolerant patients in CML phase, MCyR rate was higher at the 
median 15-month point. In ALL patients, 42% of ALL patients had major he-
matological responses.
For CML patients, dasatinib had significant advantages in effectiveness in terms of 
a complete cytogenetic response while the MCyR was not statistically significant at 
either the 12 wk or 1 yr time point. Study CA 180-015 showed evidence of rescue in 
a significant minority of patients.
Economic or 
BIA evidence
The 1-year cost of dasatinib was lower than the comparator. Regarding CML, drug cost is high and the ICER is sensitive to the imatinib dose and 
the dasatinib price should be calculated considering dasatinib 140 mg is no greater 
than the price for imatinib 670 mg. Regarding ALL, the ICER range was $45,000 to 
$75,000. The listing of dasatinib for the small patient group was consistent with the 
‘Rule of Rescue’ guideline.
Cetuximab
Recommendation Rejection (May 21, 2008) Approval (Jul 2010)
No. of Meetings Two Seven
Medical necessity Not for rare disease
Comparators Cetuximab+irinotecan vs. FOLFOX, CapeOX, S-1, or capecitabine BSC
Clinical evidence Study 007 trial: cetuximab vs. cetuximab+irinotecan: OS response (10.8% vs. 
22.9%) was significant with no significant difference in survival time (8.6 vs. 
6.9 months). However, no clinical trial data in comparison with other second-
line chemotherapy was available.
Accepted with the evidence of the CO17 trial cetuximab+chemotherapy vs. BSC, 
FOLFOX, FOLFIRI, cetuximab+irinotecan, cetuximab+oxaliplatin. Bevacizumab is 
not an appropriate comparator.
Economic or BIA 
evidence
The assumption that both ASC and BSC had the same effectivenesswas not ac-
ceptable. Unclear cost-effectiveness for 2nd and 3rd line treatment of approved 
indication. In future, a model comparing with salvage therapy (S-1) should 
be developed.
The weighted ICER was between $45,000 and $75,000/QALY, which PBAC consid-
ered high but acceptable. The accuracy of K-RAS test should be assessed; this was 
being funded by the sponsor. 
Topotecan oral
Recommendation Approval (Jun 18, 2009) Rejection (Jul 2010) 
No. of Meetings Two One
Comparators/
Medical necessity
Topotecan IV/Not necessary BSC
Clinical evidence Topotecan plus BSC improves overall survival and quality of life compared 
with BSC. No difference compared with topotecan IV.
Uncertain clinical benefit: the submission and clinical trial did not provide a well-
defined inclusion criterion for “contraindication to CAV” and “patients for whom IV 
therapy is inappropriate” as the revised restrictions proposed by the sponsor according 
to pre-PBAC response.
Economic or BIA 
evidence
Topotecan cost for one cycle is lower than the comparator The ICER was sensitive to the effect of male gender and the presence of liver me-
tastases; $75,000 to $105,000/QALY for males and for less than $15,000/QALY for 
females. Thus, the ICER is high and uncertain.
Nilotinib
Recommendation Conditional approval (Aug 20, 2009) Approval (Mar 2008)
No. of Meetings Two One
Comparators/ 
Medical necessity
Dasatinib, high-dose imatinib/Not necessary Dasatinib, high-dose imatinib
Clinical evidence No clinical data on direct comparison. Also, clinical trials used different 
definitions for imatinib intolerance, and thus, the data were not useful.
For the chronic phase, both nilotinib and dasatinib are highly effective. However, 
because the data did not come from a single trial, it was difficult to say which one 
was better. For accelerated phase, insufficient data to conclude its non-inferiority.
Economic or BIA 
evidence
ICER value was not cost-effective. The drug therapy cost was higher than 
comparators for chronic phase while it was lower for accelerated phase. 
The price as a weighted average of comparators’ prices was accepted. 
Cost minimization analysis 
(the equi-effective dose: nilotinib 800 mg vs. dasatinib 140 mg).
Lapatinib
Recommendation Approval (Nov 19, 2009) Approval (Nov 2007). 
For lapatinib continuation beyond progression, a risk-share arrangement is 
recommended.
No. of Meetings Three Two
Comparators/
Medical necessity
Capecitabine monotherapy, gemcitabine+vinorelbine/Not necessary Capecitabine, trastzumabmonotherapy, trastzumab+vinorelbine, 
trastzumab+capecitabine, trastzumab+taxane, gemcitabine+taxane.
Clinical evidence Effective for CNS metastases, Lapatinib+capecitabine has been used without 
reimbursement in practice.
The conservative assumption that trastzumab continuation was at least as effective as 
lapatinib+capecitabine was accepted.
Economic or BIA 
evidence
Lower costs for patients whose tumors overexpress HER2 and have 
progressedafter treatment with trastuzumab. Also less expensive than the 
trastuzumab therapy. The ICER compared capecitabine monotherapy or 
emcitabine+vinorelbine for advanced/metastatic breast cancer patients, which 
was acceptable.
The ICER was extremely sensitive to the rate of lapatinib for continued treatment 
with trastuzumab and the sponsor’s price offer with a 50% rate of substitution of 
trastzumab resulted in an ICER of $45,000 to $75,000.
*ALL, acute lymphoblastic leukemia; ASC, active supportive care; BIA, budget impact analysis; BSC, best supportive care; CAV, cyclophosphamide + doxorubicin + 
vincristine; CapeOX, capecitabine + oxaliplatin; CML, chronic myeloid leukemia; CNS, central nervous system; DREC, Drug Reimbursement Evaluation Committee; 
FOLFIRI, folinic acid + fluorouracil + irinotecan; FOLFOX, folinic acid + fluorouracil + oxaliplatin; HER2, human epidermal growth factor receptor 2; ICER, Incremental 
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guideline for these decisions, but rather these depended on 
the interpretation of evidence by DREC and the dynamics 
of pharmaceutical markets.
 Recently, the plan to re-evaluate approximately 20,000 
listed drugs was rescinded in Korea, resulting in a price 
cut en bloc for all listed drugs rather than reducing the 
number of listed drugs. It is difficult to sort out disposable 
drugs among competitors on the national drug formulary. 
Further, especially when two new drugs are on par with 
one another in terms of both clinical and economic 
outcomes (such as dasatinib and nilotinib), the decision 
to reimburse only one should be justified and assured to 
the public. However, there has been no discussion about 
fairness for applying economic evaluation hurdles only to 
new drugs developed from the time when the HTA system 
was been implemented in 2007.
 Publicity of decision processes and rationales: Because 
the figures of ICER values or the drug prices evaluated by 
DREC have been redacted from the PSDs, it is not possible 
for the public to make value judgments based on missing 
numerical evidence. On the contrary, this information is 
disclosed in the reports of PBAC and NICE. The aim of 
publishing the PSDs was to explain the decision results 
and the reasoning of the committee to the public. No matter 
the reasons for non-disclosure, it may be contradictory that 
the public is expected to judge and trust a decision based 
on economic evidence that is not provided to the public.
 While privileging the primary data relevant to the 
Korean healthcare system in drawing cost-effectiveness 
evidences, however, HIRA has not made public much 
empirical data, such as budget figures and utilization 
amounts, which are under the jurisdiction of HIRA itself 
(Health Insurance Review and Assessment Service: HIRA, 
2007). Indeed, the interviewee oncologists agreed that if 
HIRA shared utilization and expenditures information, 
those unanswered assumptions in the HTA submissions 
would be properly questioned and considered. 
Discussion
This paper has presented the pitfalls of the HTA-
based Korean centralized prescription drug review policy 
for reimbursement decisions. Many of the rationales 
and empirical evidences used in deriving decisions for 
oncology drugs by DREC were not agreed upon because 
of the lack of clear relevance, despite all of the information 
the PSDs contained. Moreover, reimbursement policies for 
cancer drugs in Korea have not been sufficiently accessible 
to the public in a timely manner. Evidentiary factors were 
not consistently applied to listing decisions and were not 
recorded on the PSDs of the DREC. The information 
related to the process and reviewers of the HTA were 
seldom delineated on the PSDs either, preventing the 
publicity of reimbursement decisions and their rationale. 
Because of the hasty adoption of the HTA evaluation, 
there may have been a delay in paying particular attention 
to constructing detailed manuals and concrete processes 
for assessing HTA reports, as well as for rendering 
recommendation decisions public for accountability.
Furthermore, we found that normative and ethical 
values about new oncology drugs were rarely evaluated. 
Indeed, by focusing on economic and clinical evidence, 
the evaluation system in Korea has neglected the ethical 
issues which are intrinsic attributes of HTAs. Economic 
evaluation with cost-effectiveness analysis originated from 
utilitarian theory, and accordingly, policy decisions based 
on cost-effective evidence would reimburse a drug which 
then maximizes its average utility among the society. In 
the view of utilitarianism, decisions motivated by societal 
Table 3. Evidentiary Factors in DREC Decisions on Reimbursement Applications for Cancer Drugs Compared 
with NICE Decisions
Evaluation 
point
DREC Decision PBAC Decision
Fulvestrant
Recommendation Rejection (Sep 26, 2008) In progress (issue date: Aug 2010)
Currently listed as 2nd line therapy
No. of Meetings Two
Medical necessity Exemestane/Not necessary Anastrozole, exemestane, letrozole
Clinical evidence While clinical guideline suggests this drug therapy for 2nd line, its approval is 
for 3rd line therapy about which no clinical trial had been conducted.
Endocrine therapy is appropriate for about 70% of hormone receptor-positive 
advanced breast cancer patients.
Economic or 
BIA evidence
ICER shows uncertain cost-effectiveness. The costs during median TTP 
(3 months) were higher than the costs of exemestane.
Trabectedin
Recommendation Rejection (Mar 25, 2010) Approval (Feb 2010)—review date (Feb 2013)
No. of Meetings Two
Comparators/
Medical necessity
Gemcitabine + docetaxel/Not necessary; no alternative registered for the same 
indication, but gemcitabine + docetaxel could be used clinically.
BSC/soft tissue sarcoma is a rare condition and there is no licensed treatment option 
apart from trabectedin.
Clinical evidence No clinical data on direct comparison. Uncertain clinical effectiveness for 
trabectedin (RR: 5.6%; TTP: 3.7 months) compared with gemcitabine+ 
docetaxel (RR: 17%; PFS: 6.2 months) in comparison with gemcitabine.
Patients with the licensed dose of trabectedin showed better PFS than patients with 
an active regimen of BSC.
Economic or BIA 
evidence
Drug cost for 1 cycle is expensive and the price was greater than the weighted 
average price of other countries. Difficult to determine the weighted average 
cost of the comparator because gemcitabine+docetaxel therapy is not 
standardized, requiring permission before use.
The ICER of £34,500/QALY in the light of the end-of-life criteria was within the 
current threshold range and acceptable.
*BIA, budget impact analysis; BSC, best supportive care; DREC, Drug Reimbursement Evaluation Committee; ICER, incremental cost effectiveness ratio; NICE, National 
Institute for Health and Clinical Excellence; PFS, progression-free survival; RR, risk ratio; TTP, time to progression; QALY, quality-adjusted life year
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duty or sympathy rather than those being grounded on 
scientific evidence infringe on allocative efficiency. 
However, considering that both utilitarian and moral 
behaviours have the same goal (which is the production 
of maximal utility), it would not be an incongruous work 
to examine both cost-effectiveness and ethical aspects 
altogether in drug reimbursement assessment (Pinkerton, 
2002). The social benefit arises from an improvement of 
citizens’ health per se, but it should be further increased 
by reinforcing the belief that they live in a system that 
cares their life and accepts their priorities (McKie and 
Richardson, 2003).
Because ethics has only recently been emphasized 
as a part of the HTA, little consensus had been made on 
the methods for incorporating ethics into HTA systems 
(Hofmann, 2008; Burls et al., 2011). Final decisions 
could be different across different HTA systems because 
a drug could have different economic or ethical values 
depending on the society. However, if the decision-making 
was brought forth based on rational evidence that included 
both empirical and ethical concerns, and if the decision-
making process was indeed a fair evaluation procedure 
open to the public, then it likely would gain universal 
acceptance. In this sense, procedural justice may be the 
most prominent feature to consider in policy-making, 
because although not infallible, it is certainly the best 
procedure generally acceptable to the society (Abelson et 
al., 2007; Droste et al., 2010). Thus, transparent criteria 
at all decision stages and an explicit discussion of formal 
criteria and procedures are essential for accountable 
policy-making. Norman Daniels’ theory “Accountability 
for Reasonableness” suggests four conditions aimed at 
solving policy decision problems that involve legitimacy 
and fairness: Condition i, publicly accessible rationales; 
Condition ii, reasonableness or relevance on rationales; 
Condition iii, dispute resolution procedures; and Condition 
iv, voluntary or public regulation (Daniels and Sabin, 
1997). 
Regarding these four conditions, our research shows 
that the overall criteria of publicity and reasonable 
rationale in the review for reimbursement decisions have 
not been met. Ethical values about each new oncology 
drug have not been sufficiently sought. Furthermore, 
appropriate communication of the evidence should include 
clinicians, patients, and the general public in the future 
(Drummond et al., 2009; Oortwijn et al., 2010). Efforts of 
being ready to be accountable for the policy decisions and 
their rationales are called for if the ethics of reimbursement 
decisions is worth considering in Korea. Indeed, without 
the concept about fairness in policy decisions, the public 
is unlikely to accept any decisions even they are in fact 
reasonable (Daniels et al., 2003). 
In drawing the results of this study, the essential 
features of the PSDs may not have been overtly specified 
by the authors. However, the qualitative analysis and 
review by the investigators on the clinical, economic, and 
ethical aspects of decisions and the evaluation process 
for each new oncology drug noted in the PSDs makes it 
possible for the present study to incorporate extensive 
insights on ethical concerns that are lacking in the current 
HTA policy. Although not representing the entire society 
for the value of oncology drugs, the oncologists invited 
in the analytical discussion had provided expertise on the 
empirical evidence as well as opinions about what was 
missed in terms of the ethical values throughout DREC’s 
reimbursement decisions for oncology drugs in Korea.
The reimbursement decision-making for oncology 
drugs needs to be improved in consideration of the ethical 
aspects of the HTA-based policy in Korea. Decisions 
should be based on empirical evidence with clear 
relevance which is agreed upon by the public. Ethical 
values should be addressed for each of the new drugs. 
Most of all, encompassing the public accountability for 
reasonableness toward the decisions and the rationales is 
certainly required for fair limit-setting policy on oncology 
drug treatments.
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